Bacillus
subtilis
is a major workhorse
for enzyme production in industrially relevant quantities. Compared
to mammalian-based expression systems,
B. subtilis
presents intrinsic advantages, such as high growth rates, high space-time
yield, unique protein secretion capabilities, and low maintenance
costs. However,
B. subtilis
shows clear
limitations in the production of biopharmaceuticals, especially proteins
from eukaryotic origin that contain multiple disulfide bonds. In the
present study, we deployed genome minimization, signal peptide screening,
and coexpression of recombinant thiol oxidases as strategies to improve
the ability of
B. subtilis
to secrete
proteins with multiple disulfide bonds. Different genome-reduced strains
served as the chassis for expressing the model protein
Gaussia
Luciferase (GLuc), which contains five disulfide bonds. These chassis
lack extracellular proteases, prophages, and key sporulation genes.
Importantly, compared to the reference strain with a full-size genome,
the best-performing genome-minimized strain achieved over 3000-fold
increased secretion of active GLuc while growing to lower cell densities.
Our results show that high-level GLuc secretion relates, at least
in part, to the absence of major extracellular proteases. In addition,
we show that the thiol–disulfide oxidoreductase requirements
for disulfide bonding have changed upon genome reduction. Altogether,
our results highlight genome-engineered
Bacillus
strains
as promising expression platforms for proteins with multiple disulfide
bonds.